ETHIC Act
- Bill Number
- S. 2276
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Commerce
- Status
- Introduced
- Latest Action
- 2025-07-15: Read twice and referred to the Committee on the Judiciary.
- Last Updated
- 2025-12-05T22:08:07Z
AI-Generated Summary
Purpose
The Eliminating Thickets to Increase Competition Act (ETHIC Act) aims to reduce "patent thickets"—clusters of related patents owned by the same entity that can delay competition from generic drugs and biosimilars. By limiting how many patents can be used in infringement lawsuits against these competitors, the bill seeks to promote faster market entry for lower-cost alternatives to brand-name drugs and biologics.
Key Provisions
- Limitation on Patent Assertions: In patent infringement lawsuits under 35 U.S.C. § 271(e)—a safe harbor provision that protects activities related to FDA approvals—plaintiffs (typically brand-name drug makers) can assert no more than one patent per Patent Group against specific parties.
- Affected Parties: This restriction applies to:
- Companies submitting or holding FDA approvals for generic drugs under abbreviated pathways (sections 505(b)(2) or (j) of the Federal Food, Drug, and Cosmetic Act).
- Companies submitting or holding licenses for biosimilar biological products (section 351(k) of the Public Health Service Act).
- Entities making, using, selling, importing, or distributing these approved generics or biosimilars.
- One-Time Assertion Rule: Once a patent from a Patent Group is asserted against a party, no additional patents from the same group can be used in future lawsuits against that party.
- Definition of Patent Group: A group consists of two or more commonly owned patents or applications linked by disclaimers filed under 35 U.S.C. § 253. These disclaimers are used to avoid "obviousness-type double patenting" (a situation where multiple patents claim similar inventions that are too similar to each other). Patents referencing the same disclaimer or being referenced by it form one group.
- Applicability: The rules apply to FDA applications or licenses submitted on or after the date the Act is enacted.
Significant Changes to Existing Law
- Amends 35 U.S.C. § 271(e) by adding a new subsection (7), introducing the first explicit limit on the number of related patents that can be enforced in safe harbor infringement actions.
- Previously, patent holders could assert multiple related patents against generics or biosimilars, potentially creating barriers to market entry through prolonged litigation. This change curtails that practice for patents tied together by double-patenting disclaimers, streamlining defenses for challengers.
Potential Impacts
- On Government Agencies: The FDA may see indirect effects through faster generic and biosimilar approvals, potentially reducing review backlogs related to patent disputes, though no direct changes to FDA processes are made.
- On Citizens: Could lower drug prices by accelerating access to affordable generics and biosimilars, benefiting consumers, especially those with chronic conditions reliant on expensive medications.
- On International Relations: Minimal direct impact, but enhanced U.S. competition in pharmaceuticals might influence global drug pricing and trade dynamics, potentially pressuring international pharma markets to follow suit.
- Overall, the bill could reduce litigation costs and encourage innovation in non-patent strategies for drug developers.
Main Stakeholders Affected
- Brand-Name Pharmaceutical Companies: Face restrictions on using patent portfolios to block competitors, potentially shortening exclusivity periods and reducing revenue from high-priced drugs.
- Generic Drug and Biosimilar Manufacturers: Gain stronger protections against multi-patent lawsuits, easing entry into the market and lowering development risks.
- Consumers and Healthcare Providers: Benefit from increased competition, which may drive down costs and improve access to medications.
- Patent Holders and Litigants: Attorneys and courts involved in drug patent disputes may handle fewer complex, multi-patent cases.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces the Hatch-Waxman Act's balance between innovation incentives and generic competition by targeting abusive patent clustering; may reduce frivolous lawsuits but could face challenges if seen as unduly limiting property rights in patents.
- Constitutional: No major issues anticipated, as it regulates patent enforcement without altering core patent validity or grant processes, aligning with Congress's authority over patent law under Article I, Section 8.
- Political: Bipartisan support (introduced by Sens. Welch, Hawley, and Klobuchar) signals broad consensus on curbing pharma monopolies; could influence ongoing debates on drug pricing and antitrust in healthcare, potentially paving the way for similar reforms in other sectors.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Hawley, Josh [R-MO], Sen. Klobuchar, Amy [D-MN]
Recent Actions
- 2025-07-15: Read twice and referred to the Committee on the Judiciary.
- 2025-07-15: Introduced in Senate
Bill Versions
- Eliminating Thickets to Increase Competition Act — issued 2025-07-15 — PDF (4 pages)